Conclusions
colorectal peritoneal metastases, CRS
LOSS OF APPETITE
In patients with resectable colorectal peritoneal metastases randomized to perioperative systemic therapy or CRS–HIPEC alone, all predefined PROs were comparable between both arms and returned to baseline at 3 or 6 months postoperatively. Though several PROs worsened after neoadjuvant treatment, all of these (except for loss of appetite) returned to baseline at 3 or 6 months postoperatively. Together with the trial’s previously reported feasibility and safety data, these findings show acceptable tolerability of perioperative systemic therapy in this setting and justify a phase III trial.